Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Blueprint Medicines
Blueprint Medicines
FDA Grants Regular Approval of Gavreto for Metastatic NSCLC Subset
FDA Grants Regular Approval of Gavreto for Metastatic NSCLC Subset
Cure Today
Genentech
Blueprint Medicines
Gavreto
non-small cell lung cancer
Flag link:
Roche pulls a Gavreto approval before Blueprint severance, citing unfeasible trial
Roche pulls a Gavreto approval before Blueprint severance, citing unfeasible trial
Fierce Pharma
Roche
Blueprint Medicines
cancer
Gavreto
accelerated approvals
FDA
Flag link:
What Will AbbVie Buy Next?
What Will AbbVie Buy Next?
Motley Fool
AbbVie
M&A
Blueprint Medicines
Krystal Biotech
Flag link:
Blueprint's Ayvakit picks up long-awaited FDA approval in indolent systemic mastocytosis
Blueprint's Ayvakit picks up long-awaited FDA approval in indolent systemic mastocytosis
Fierce Pharma
Blueprint Medicines
Ayvakit
FDA
indolent systemic mastocytosis
systemic mastocytosis
Flag link:
FDA lifts partial hold on Blueprint's CDK2 inhibitor
FDA lifts partial hold on Blueprint's CDK2 inhibitor
Endpoints
Blueprint Medicines
cancer
CDK2 inhibitor
FDA
Flag link:
Ahead of FDA decision, Blueprint puts out full data for expanded Ayvakit label
Ahead of FDA decision, Blueprint puts out full data for expanded Ayvakit label
Endpoints
Blueprint Medicines
FDA
Ayvakit
systemic mastocytosis
Flag link:
Roche and Blueprint agree to end collaboration for cancer drug Gavreto
Roche and Blueprint agree to end collaboration for cancer drug Gavreto
Endpoints
Roche
Gavreto
Blueprint Medicines
cancer
Flag link:
Blueprint gears up for Ayvakit expansion, with blockbuster sales on the line
Blueprint gears up for Ayvakit expansion, with blockbuster sales on the line
Fierce Pharma
Blueprint Medicines
Ayvakit
FDA
systemic mastocytosis
Flag link:
Blueprint drug succeeds in rare disease study important to its market prospects
Blueprint drug succeeds in rare disease study important to its market prospects
BioPharma Dive
Blueprint Medicines
systemic mastocytosis
clinical trials
Ayvakit
Flag link:
Blueprint secures access to more than $1B in funding through two new deals
Blueprint secures access to more than $1B in funding through two new deals
BioPharma Dive
Blueprint Medicines
funding
Flag link:
Opportunities arise for once-spurned partners
Opportunities arise for once-spurned partners
EP Vantage
Pfizer
Biohaven
licensing
M&A
Aurinia
Bristol Myers Squibb
AbbVie
Alector
Arcus Biosciences
Biogen
Blueprint Medicines
CureVac
Gilead Sciences
GSK
Incyte
MorphoSys
Roche
Nestle
SAGE Therapeutics
Sarepta Therapeutics
Seres Therapeutics
Syndax
Flag link:
Riding success of Roche-partnered lung cancer drug, Blueprint makes $250M play for Lengo's preclinical work
Riding success of Roche-partnered lung cancer drug, Blueprint makes $250M play for Lengo's preclinical work
Fierce Biotech
Blueprint Medicines
M&A
Lengo Therapeutics
Flag link:
Scientific co-founder of Blueprint Medicines launches Recludix with $60M, 15-year Seagen exec steering the ship
Scientific co-founder of Blueprint Medicines launches Recludix with $60M, 15-year Seagen exec steering the ship
Fierce Biotech
Recludix Pharma
STAT inhibitors
Blueprint Medicines
funding
Flag link:
Pfizer's CEO Wants to Go Shopping: 3 Potential Companies on His Radar
Pfizer's CEO Wants to Go Shopping: 3 Potential Companies on His Radar
Motley Fool
Pfizer
M&A
Blueprint Medicines
Aurinia Pharmaceuticals
Atea Pharmaceuticals
Flag link:
Rare Blood Disease Drug Win Marks Fourth Approval for Blueprint Medicines
Rare Blood Disease Drug Win Marks Fourth Approval for Blueprint Medicines
BioSpace
Blueprint Medicines
Ayvakit
MCL
systemic mastocytosis
FDA
Flag link:
FDA Action Alert: Blueprint, Orphazyme and Eton
FDA Action Alert: Blueprint, Orphazyme and Eton
BioSpace
FDA
Blueprint Medicines
avapritinib
Orphazyme
arimoclomol
Eton Pharmaceuticals
Flag link:
Fortunes diverge for solo drug launchers
Fortunes diverge for solo drug launchers
EP Vantage
drug launches
Intra-Cellular Therapies
Biocryst
Horizon Therapeutics
Karyopharm Therapeutics
Blueprint Medicines
Zogenix
Esperion
Epizyme
Aurinia Pharmaceuticals
Global Blood Therapeutics
Flag link:
The Week Ahead In Biotech: FDA Decision On G1 Therapeutics, Earnings In The Mix For Light Calendar Week
The Week Ahead In Biotech: FDA Decision On G1 Therapeutics, Earnings In The Mix For Light Calendar Week
Yahoo/Benzinga
earnings
FDA
G1 Therapeutics
trilaciclib
Zoetis
EXACT Sciences
Blueprint Medicines
Ironwood Pharmaceuticals
Flag link:
Roche, Blueprint raise pressure on Lilly with new Gavreto approval
Roche, Blueprint raise pressure on Lilly with new Gavreto approval
Pharmaforum
Roche
Blueprint Medicines
Gavreto
thyroid cancer
Retevmo
Eli Lilly
Flag link:
Blueprint plots return to FDA with new Ayvakit data in rare condition — and the analysts cheer
Blueprint plots return to FDA with new Ayvakit data in rare condition — and the analysts cheer
Endpoints
Blueprint Medicines
Roche
FDA
Ayvakit
Flag link:
Pages
1
2
3
next ›
last »